We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

DiscoveRx Launches Assay for Beta-Arrestin Based Screening

Read time: Less than a minute

DiscoveRx has announced the release of the PathHunter™ Flash Detection Kit to enable ß-arrestin recruitment by a GPCR in 30 seconds, permitting screens of up to 1,000,000 compounds in 48 hours.

Unlike lengthy reporter gene assays, PathHunter ß-arrestin assays are direct and hence minimize the opportunity for off-target effects. A ligand-activated, GPCR-arrestin interaction combines two ß-galactosidase fragments, enabling rapid chemiluminescent detection in a homogeneous format. The kit is designed for whole class of plate readers with onboard fluidics and flash detection mode.

Additionally, screening campaigns can be accelerated by conducting ß-arrestin and calcium assays in the same well on same instrument, without need of cell fixation, when using instruments capable of real-time fluorescence and flash chemiluminescence.

With an expanding list of GPCR Beta-Arrestin assays (>90 assays) being added to its product offering, DiscoveRx has a solution for virtually any GPCR screening campaign.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.